Abstract：
OBJECTIVE: Anthracycline-cyclophosphamide followed by docetaxel-containing chemotherapy is effective for perioperative breast cancer treatment. However, these treatments frequently induce oral mucositis (OM), with an incidence ranging from 20 to 50%. The association of OM development between different chemotherapeutic treatments remains unclear. Consequently, this study aimed to compare OM development during docetaxel-containing chemotherapy between patients with and without OM experience during previous anthracycline-cyclophosphamide treatments to assess the association between OM development and treatment regimens.
METHODS: Seventy-two patients with breast cancer receiving anthracycline-cyclophosphamide followed by docetaxel-containing chemotherapy as a perioperative treatment were categorized into the control (no prior OM experience with anthracycline-cyclophosphamide) and OM-experience (OM development during previous treatment) groups and retrospectively evaluated. The primary endpoint was the incidence of all-grade OM in the first docetaxel-containing chemotherapy cycle. Additionally, the incidences of OM and dysgeusia during all treatment cycles and factors associated with the incidence of OM were evaluated.
RESULTS: The incidence of all-grade OM in the first cycle was significantly higher in the OM-experience group (54.2%) than in the control group (10.4%; P < 0.0001). Furthermore, its incidence in all treatment cycles was higher in the OM-experience group (66.7%) than in the control group (12.5%, P < 0.0001). However, the incidence of dysgeusia did not differ between the groups. Multivariate logistic regression analysis revealed OM experience during previous anthracycline-cyclophosphamide treatment and concomitant pertuzumab use as independent risk factors for OM development in subsequent docetaxel-containing chemotherapy.
CONCLUSIONS: Our study suggests that patients experiencing OM with anthracycline-cyclophosphamide during perioperative breast cancer treatment exhibit symptoms following subsequent docetaxel-containing chemotherapy.
METHODS: Seventy-two patients with breast cancer receiving anthracycline-cyclophosphamide followed by docetaxel-containing chemotherapy as a perioperative treatment were categorized into the control (no prior OM experience with anthracycline-cyclophosphamide) and OM-experience (OM development during previous treatment) groups and retrospectively evaluated. The primary endpoint was the incidence of all-grade OM in the first docetaxel-containing chemotherapy cycle. Additionally, the incidences of OM and dysgeusia during all treatment cycles and factors associated with the incidence of OM were evaluated.
RESULTS: The incidence of all-grade OM in the first cycle was significantly higher in the OM-experience group (54.2%) than in the control group (10.4%; P < 0.0001). Furthermore, its incidence in all treatment cycles was higher in the OM-experience group (66.7%) than in the control group (12.5%, P < 0.0001). However, the incidence of dysgeusia did not differ between the groups. Multivariate logistic regression analysis revealed OM experience during previous anthracycline-cyclophosphamide treatment and concomitant pertuzumab use as independent risk factors for OM development in subsequent docetaxel-containing chemotherapy.
CONCLUSIONS: Our study suggests that patients experiencing OM with anthracycline-cyclophosphamide during perioperative breast cancer treatment exhibit symptoms following subsequent docetaxel-containing chemotherapy.
摘要：
目的：蒽环类环磷酰胺联合多西他赛化疗是乳腺癌围手术期治疗的有效方法。然而,这些治疗经常引起口腔粘膜炎（OM），发病率从20%到50%不等。不同化疗治疗之间OM发展的关联仍不清楚。因此,本研究旨在比较既往蒽环类-环磷酰胺治疗期间有或无OM经历的多西他赛化疗期间OM的发展,以评估OM发展与治疗方案之间的相关性.
方法：将72例接受蒽环类环磷酰胺和多西他赛化疗作为围手术期治疗的乳腺癌患者分为对照组（既往没有使用蒽环类环磷酰胺的OM经验）和OM经验（既往治疗期间的OM发展）组，并进行回顾性评估。主要终点是第一个包含多西他赛的化疗周期中所有级别OM的发生率。此外,评估了所有治疗周期中OM和味觉障碍的发生率以及与OM发生率相关的因素.
结果：OM体验组第一周期中所有级别OM的发生率（54.2%）明显高于对照组（10.4%；P<0.0001）。此外，在所有治疗周期中，OM体验组（66.7％）的发生率均高于对照组（12.5％，P<0.0001)。然而,两组间味觉障碍的发生率无差异.多因素logistic回归分析显示，在过去蒽环类抗生素-环磷酰胺治疗期间的OM经验和同时使用帕妥珠单抗是随后含多西他赛化疗中OM发展的独立危险因素。
结论：我们的研究表明，在围手术期乳腺癌治疗期间接受蒽环类-环磷酰胺治疗的患者在随后的多西他赛化疗后出现症状。
方法：将72例接受蒽环类环磷酰胺和多西他赛化疗作为围手术期治疗的乳腺癌患者分为对照组（既往没有使用蒽环类环磷酰胺的OM经验）和OM经验（既往治疗期间的OM发展）组，并进行回顾性评估。主要终点是第一个包含多西他赛的化疗周期中所有级别OM的发生率。此外,评估了所有治疗周期中OM和味觉障碍的发生率以及与OM发生率相关的因素.
结果：OM体验组第一周期中所有级别OM的发生率（54.2%）明显高于对照组（10.4%；P<0.0001）。此外，在所有治疗周期中，OM体验组（66.7％）的发生率均高于对照组（12.5％，P<0.0001)。然而,两组间味觉障碍的发生率无差异.多因素logistic回归分析显示，在过去蒽环类抗生素-环磷酰胺治疗期间的OM经验和同时使用帕妥珠单抗是随后含多西他赛化疗中OM发展的独立危险因素。
结论：我们的研究表明，在围手术期乳腺癌治疗期间接受蒽环类-环磷酰胺治疗的患者在随后的多西他赛化疗后出现症状。
